Haleon (LON:HLN) PT Lowered to GBX 383 at Barclays

Haleon (LON:HLN) had its target price lowered by Barclays from GBX 390 ($4.94) to GBX 383 ($4.85) in a report issued on Tuesday morning, Marketbeat reports. The brokerage currently has an overweight rating on the stock.

Haleon Price Performance

Shares of LON:HLN opened at GBX 323.20 ($4.09) on Tuesday. The company’s fifty day moving average price is GBX 324.78 and its 200-day moving average price is GBX 327.19. The firm has a market capitalization of £29.51 billion and a price-to-earnings ratio of 2,938.18. Haleon has a one year low of GBX 306.80 ($3.88) and a one year high of GBX 357.65 ($4.53). The company has a debt-to-equity ratio of 57.42, a current ratio of 1.04 and a quick ratio of 0.93.

Haleon Increases Dividend

The firm also recently announced a dividend, which will be paid on Thursday, May 16th. Investors of record on Thursday, March 14th will be issued a dividend of GBX 4.20 ($0.05) per share. The ex-dividend date of this dividend is Thursday, March 14th. This represents a dividend yield of 1.34%. This is a positive change from Haleon’s previous dividend of $1.80. Haleon’s dividend payout ratio (DPR) is currently 5,454.55%.

Insider Activity at Haleon

In related news, insider Tobias Hestler sold 23,564 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of GBX 329 ($4.16), for a total transaction of £77,525.56 ($98,121.20). 22.53% of the stock is owned by insiders.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.